Skip to content
karyopharm-logo Logo for Karyopharm
Main Menu
  • Contact
  • Clinical Trials
  • Careers
  • Follow Us
  • LinkedIn
  • Twitter
  • About
    • Company Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Grants and Giving
    • Careers
      • Our Culture
      • Benefits
      • Job Opportunities
  • Technology & Research
    • Overview
    • Disease Areas of Focus: Hematologic Malignancies & Solid Tumors
      • Multiple Myeloma
      • DLBCL
    • SINE Technology (Selective Inhibitor of Nuclear Export)
    • Supporting Medical Research
    • Publications and Presentations
  • Products
  • Pipeline
    • Overview
    • Oral Selinexor
    • Oral Eltanexor
    • Oral Dual Inhibitor of PAK4 and NAMPT (KPT-9274)
    • Oral Verdinexor
    • Expanded Access
  • Media Center
  • Investors
    • Company Overview
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • SEC Filings
      • Annual Reports & Proxy Statements
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
    • Analyst Coverage
    • Investor Alerts
    • Press Releases
    • Contact Us
      • Investor FAQs
      • RSS
  • Resources
    • Patient Resources
    • Healthcare Provider Resources

Paper

Paper

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

  • External Link
Read More
Paper

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer

  • External Link
Read More
Paper

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

  • External Link
Read More
Paper

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

  • PDF (1.15 MB)
Read More
Paper

Promising Activity Of Selinexor In The Treatment Of A Patient With Refractory Diffuse Large B-Cell Lymphoma And Central Nervous System Involvement

  • External Link
Read More
Paper

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom’s macroglobulinemia

  • External Link
Read More
Paper

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis

  • External Link
Read More
Paper

Selective Inhibition of Nuclear Export with Selinexor in Patients with Non-Hodgkin’s Lymphoma

  • External Link
Read More
Paper

A Phase I Clinical Trial of Single-Agent Selinexor in Acute Myeloid Leukemia

  • External Link
Read More
Paper

Selective inhibitor of nuclear export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3

  • PDF (19.01 MB)
Read More
1 2 3 … 7 Next
© Karyopharm, 2021. All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • Site Map